S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.10
+360.20
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.29
+1.61
+9.65%
RANI · Rani Therapeutics Holdings, Inc. Class A
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Rani Therapeutics Holdings Inc (RANI)
NASDAQ NMS - GLOBAL MARKET
Pharmaceuticals
$0.61
-0.05
(-7.14%)
● At close: October 21 at 4:00:00 PM EDT
$0.63
+0.02
(+4.13%)
Overnight:
11:24:36 PM EDT
DAY'S RANGE
$0.61
$0.61
$0.65
52-WEEK RANGE
$0.61
$0.61
$3.87
What's happening
- RANI is down 7.14% today, trading at $0.61. — Live quote
- It's trading within 3% of its 52-week low ($0.61). (Finnhub fundamentals)
- Volume today (11,121) is well below its 3-month average of 714,230. (Finnhub fundamentals)
- Reports earnings on 2026-11-05 (after market close), 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.04 actual vs. $-0.05 estimated (+21.6%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 2
Buy 8
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (11 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
RANI
-51.64%
vs S&P 500
-64.42%
1-YEAR RETURN
RANI
-70.99%
vs S&P 500
-85.55%
6-MONTH RETURN
RANI
-28.97%
3-MONTH RETURN
RANI
-5.53%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.04
Est. $-0.05
BEAT +21.6%
2026-04-26 (Q1 2026)
$-0.04
Est. $-0.05
BEAT +12.9%
2026-01-26 (Q4 2025)
$-0.07
Est. $-0.07
MISS -2.9%
2025-10-26 (Q3 2025)
$-0.12
Est. $-0.13
BEAT +4.6%
Valuation Measures & Ratios
Enterprise Value4$79.5M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)17.29
Price / Book72.64
EV4 / Revenue16.29
EV4 / EBITDA—
Profit Margin-507.05%
Operating Margin-538.81%
Return on Equity (ROE8)-73.71%
Return on Assets (ROA9)-66.43%
Avg Volume (3M)714,230
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $140.7M | $128.2M | $22.4M | $18.7M | $42.1M |
| P/E | -5.30 | -4.85 | -0.86 | -0.68 | -1.49 |
| Price/Sales | 41.18 | 68.17 | 130.34 | 109.00 | 244.76 |
| Price/Book | 3.59 | 4.51 | -2.85 | -3.36 | -13.78 |
| EV/Revenue | 39.76 | 63.04 | 184.95 | 149.78 | 307.61 |
| ROE | -67.61% | -92.94% | 332.71% | 494.06% | 927.19% |
| ROA | -43.60% | -50.89% | -257.92% | -163.00% | -117.45% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short7,249,790
Change from Prior Settlement+1.87%
% of Float—
Days to Cover (Short Ratio)11.62
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 10.8% on the provider's reported measure. Finnhub fundamentals ↗
- Latest SEC filing is Form 4, filed 2026-09-29; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -507.1%. Finnhub fundamentals ↗
- Trailing 52-week price return is -71.0%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on RANI
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.7M | $1.7M | $0 | $0 | $172.0K | $0 | $0 | $0 |
| Operating income | -$8.8M | -$8.3M | -$7.3M | -$10.5M | -$12.0M | -$11.8M | -$12.5M | -$14.0M |
| Net income | -$7.4M | -$7.0M | -$5.4M | -$6.7M | -$7.3M | -$6.8M | -$6.8M | -$7.5M |
| EPS (diluted) | $-0.04 | $-0.04 | $-0.12 | $-0.18 | $-0.22 | $-0.24 | $-0.26 | $-0.29 |
| EPS (basic) | $-0.04 | $-0.04 | $-0.12 | $-0.18 | $-0.22 | $-0.24 | $-0.26 | $-0.29 |
| Operating margin | -$517 | -$488 | — | — | -$7.0K | — | — | — |
| Net margin | -$433 | -$412 | — | — | -$4.2K | — | — | — |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $60.8M | $51.9M | $58.6M | $10.1M | $16.9M | $24.1M | $36.6M | $43.5M |
| Total liabilities | $12.9M | $16.3M | $17.1M | $22.1M | $26.1M | $29.5M | $33.1M | $37.8M |
| Stockholders' equity | $39.2M | $28.4M | $33.0M | -$7.9M | -$5.6M | -$3.1M | $2.0M | $3.1M |
| Total current assets | $56.5M | $47.1M | $53.3M | $5.0M | $11.1M | $17.8M | $29.7M | $32.4M |
| Total current liabilities | $10.6M | $13.9M | $12.7M | $19.1M | $20.6M | $20.1M | $19.9M | $20.2M |
| Cash & equivalents | $4.9M | $9.6M | $18.6M | $4.1M | $10.2M | $10.1M | $3.8M | $4.3M |
| Marketable securities (current) | — | — | — | — | — | — | — | — |
| Accounts receivable | $2.0M | $2.0M | $2.0M | — | — | $600.0K | $0 | — |
| Property, plant & equipment | $525.0K | $601.0K | $736.0K | $922.0K | $1.1M | $1.3M | $1.5M | $5.5M |
| Other non-current assets | $246.0K | $246.0K | $246.0K | $245.0K | $293.0K | $246.0K | $246.0K | $246.0K |
| Accounts payable | $1.0M | $858.0K | $309.0K | $2.5M | $1.8M | $1.5M | $1.4M | $1.6M |
| Accrued liabilities | $3.1M | $4.7M | $3.9M | $2.1M | $2.6M | $2.3M | $2.1M | $1.9M |
| Deferred revenue (current) | $5.1M | $6.8M | $6.8M | — | — | — | $0 | — |
| Short-term debt | — | — | $0 | $13.5M | $15.0M | $15.0M | $15.0M | $14.8M |
| Long-term debt | — | — | $0 | $0 | $2.2M | $5.9M | $9.6M | $13.5M |
| Common stock & paid-in capital | — | — | — | — | — | — | — | — |
| Retained earnings | -$147.0M | -$139.6M | -$132.6M | -$122.3M | -$116.9M | -$110.2M | -$102.9M | -$94.0M |
| Accumulated other comprehensive income (loss) | -$30.0K | -$8.0K | $1.0K | $3.0K | $3.0K | $2.0K | $5.0K | $8.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$9.0M | -$6.5M | $294.0K | -$5.1M | -$5.8M | -$8.1M | -$8.7M | -$8.4M |
| Investing cash flow | -$14.6M | -$2.5M | -$31.0M | $0 | $5.7M | $18.2M | $2.5M | $469.0K |
| Financing cash flow | $18.8M | -$27.0K | $44.9M | -$1.0M | $188.0K | -$3.7M | $5.6M | $7.7M |
| Free cash flow | -$9.1M | -$6.5M | $294.0K | -$5.1M | -$5.8M | -$8.2M | -$8.7M | -$8.5M |
| Capital expenditures | $32.0K | $15.0K | $0 | $0 | $37.0K | $51.0K | $31.0K | $125.0K |
| Depreciation & amortization | — | — | — | — | — | — | — | — |
| Share-based compensation | $2.4M | $2.1M | $2.2M | $2.3M | $3.3M | $3.9M | $4.0M | $4.0M |
| Deferred income taxes | — | — | — | — | — | — | — | — |
| Change in accounts receivable | $0 | $0 | $2.5M | $0 | -$1.0M | $600.0K | $0 | $0 |
| Purchases of investments | $34.5M | $23.4M | $31.0M | $0 | $0 | $2.7M | $17.7M | $18.1M |
| Debt repaid | $0 | $0 | $9.5M | $3.8M | $3.8M | $3.8M | $3.8M | $1.2M |
| Tax withholding on stock comp | $9.0K | $32.0K | $21.0K | $7.0K | $8.0K | $23.0K | $9.0K | $14.0K |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $1.6M | $1.0M | $0 | $0 | $2.7M |
| Operating income | -$38.3M | -$53.3M | -$66.1M | -$63.5M | -$51.6M |
| Net income | -$29.7M | -$30.0M | -$34.0M | -$30.6M | -$8.3M |
| EPS (diluted) | $-0.45 | $-1.05 | $-1.33 | $-1.28 | $-0.43 |
| EPS (basic) | $-0.45 | $-1.05 | $-1.33 | $-1.28 | $-0.43 |
| Operating margin | -$2.3K | -$5.2K | — | — | -$1.9K |
| Net margin | -$1.8K | -$2.9K | — | — | -$307 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Jan '24 | Dec '23 | Dec '22 |
|---|---|---|---|---|---|
| Total assets | $58.6M | $36.6M | — | $57.9M | $108.0M |
| Total liabilities | $17.1M | $33.1M | — | $32.5M | $34.0M |
| Stockholders' equity | $33.0M | $2.0M | — | $12.9M | $36.9M |
| Total current assets | $53.3M | $29.7M | — | $50.8M | $100.9M |
| Total current liabilities | $12.7M | $19.9M | — | $8.0M | $4.8M |
| Cash & equivalents | $18.6M | $3.8M | — | $5.9M | $27.0M |
| Marketable securities (current) | — | — | — | — | $98.5M |
| Accounts receivable | $2.0M | $0 | $0 | — | — |
| Property, plant & equipment | $736.0K | $1.5M | — | $6.1M | $6.0M |
| Other non-current assets | $246.0K | $246.0K | — | $246.0K | $0 |
| Accounts payable | $309.0K | $1.4M | — | $648.0K | $1.5M |
| Accrued liabilities | — | — | — | — | $2.3M |
| Deferred revenue (current) | $6.8M | $0 | — | — | — |
| Short-term debt | $0 | $15.0M | — | $4.9M | $0 |
| Long-term debt | $0 | $9.6M | — | $24.5M | $29.1M |
| Common stock & paid-in capital | — | — | — | — | — |
| Retained earnings | -$132.6M | -$102.9M | — | -$72.9M | -$38.9M |
| Accumulated other comprehensive income (loss) | $1.0K | $5.0K | — | -$12.0K | -$73.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$18.7M | -$35.5M | -$51.2M | -$46.5M | -$32.2M |
| Investing cash flow | -$7.0M | $19.8M | $29.9M | -$72.4M | -$506.0K |
| Financing cash flow | $40.3M | $13.6M | $233.0K | $29.0M | $77.1M |
| Free cash flow | -$18.8M | -$35.8M | -$52.5M | -$48.1M | -$32.8M |
| Capital expenditures | $88.0K | $268.0K | $1.2M | $1.6M | $506.0K |
| Share-based compensation | $11.8M | $16.0M | $19.0M | $15.8M | $22.6M |
| Deferred income taxes | — | — | — | $0 | $0 |
| Change in accounts receivable | $2.0M | $0 | — | — | — |
| Purchases of investments | $33.7M | $57.5M | $73.3M | $73.8M | $0 |
| Debt repaid | $20.7M | $5.0M | $0 | — | — |
| Tax withholding on stock comp | $59.0K | $47.0K | $162.0K | $626.0K | $0 |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding RANI as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2024-12-27 to 2026-09-27
Recent transactions
- Insiders have net bought 71,000 shares over the last 182 days, across 2 purchases and 0 sales.
- Most recent: Imran Talat (Chief Executive Officer) — Tax withholding of 7,928 shares on 2026-09-27.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)71,000 sh(2 txns)
Sales (open market)0 sh(0 txns)
Net Shares+71,000
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Imran Talat | Chief Executive Officer | Tax withholding | 2026-09-27 | 7,928 |
| Javadi Alireza | Chief Technical Officer | Tax withholding | 2026-09-27 | 309 |
| IMRAN MIR A | Reporting person | Open market purchase | 2026-07-21 | 36,000 |
| South Cone Investments Limited Partnership | 10% owner | Open market sale | 2025-10-21 | 4,000,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-27 | Imran Talat | Chief Executive Officer | Tax withholding | 7,928 | $0.76 |
| 2026-09-27 | Javadi Alireza | Chief Technical Officer | Tax withholding | 309 | $0.76 |
| 2026-07-21 | IMRAN MIR A | Reporting person | Open market purchase | 36,000 | $0.69 |
| 2026-07-17 | Imran Talat | Chief Executive Officer | Open market purchase | 35,000 | $0.72 |
| 2026-06-27 | Javadi Alireza | Chief Technical Officer | Tax withholding | 309 | $0.74 |
| 2026-06-27 | Imran Talat | Chief Executive Officer | Tax withholding | 7,927 | $0.74 |
| 2026-03-27 | Javadi Alireza | Chief Technical Officer | Open market sale | 386 | $0.78 |
| 2026-03-27 | Imran Talat | Chief Executive Officer | Tax withholding | 9,099 | $0.81 |
| 2026-03-22 | Imran Talat | Chief Executive Officer | Tax withholding | 8,916 | $1.13 |
| 2025-12-27 | Imran Talat | Chief Executive Officer | Tax withholding | 7,906 | $1.40 |
| 2025-10-23 | IMRAN MIR A | Reporting person | Open market purchase | 2,083,334 | $0.60 |
| 2025-10-21 | South Cone Investments Limited Partnership | 10% owner | Open market sale | 4,000,000 | $2.77 |
| 2025-10-20 | South Cone Investments Limited Partnership | 10% owner | Open market sale | 1,923,000 | $2.41 |
| 2025-09-27 | Imran Talat | Chief Executive Officer | Tax withholding | 9,077 | $0.48 |
| 2025-06-27 | Imran Talat | Chief Executive Officer | Tax withholding | 9,076 | $0.55 |
| 2024-12-27 | Imran Talat | Chief Executive Officer | Open market sale | 8,014 | $1.41 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 07:31 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-29 | 4 | 2026-09-27 | View on SEC.gov → |
| 2026-09-29 | 4 | 2026-09-27 | View on SEC.gov → |
| 2026-08-13 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-13 | 8-K | 2026-08-13 | View on SEC.gov → |
| 2026-08-04 | 4 | 2026-08-03 | View on SEC.gov → |
| 2026-08-04 | 8-K | 2026-08-01 | View on SEC.gov → |
| 2026-07-23 | 4 | 2026-07-21 | View on SEC.gov → |
| 2026-07-21 | 4 | 2026-03-27 | View on SEC.gov → |
| 2026-07-21 | 4 | 2026-07-17 | View on SEC.gov → |
| 2026-07-21 | 4 | 2024-12-27 | View on SEC.gov → |
| 2026-07-21 | 4 | 2026-07-17 | View on SEC.gov → |
| 2026-06-30 | 8-K | 2026-06-24 | View on SEC.gov → |
Recent news
Headlines about RANI (Rani Therapeutics Holdings, Inc. Class A). Links open the publisher — we don’t host full articles.
-
Rani Therapeutics Eyes 2027 Obesity Data as Oral Biologics Platform Advances
Yahoo Finance · 2026-10-22 -
Countryfile's Anita Rani shares verdict on working with TV farmer for new show
Wales Online · 2026-10-21 -
Rani Therapeutics at Chardan healthcare conference: platform gains traction By Investing.com
Investing.com Nigeria · 2026-10-21 -
Apsara Rani Breaks Her Glamorous Image with a Challenging Role in Bollywood Debut Lohitaksha
Lokmat Times · 2026-10-20 -
Rani Therapeutics Holdings Insiders Placed Bullish Bets Worth US$1.31m
Simply Wall Street · 2026-10-19 -
Kajol, Bipasha Basu, Mouni Roy and more celebs visit North Bombay Durga Puja pandal on Ashtami; Rani...
Moneycontrol.com · 2026-10-18 -
Rani Mukerji News
The Times of India · 2026-10-18 -
Rani Mukerji skips Sashti and Saptami celebrations as late mother Krishna Mukerji’s photo placed among fa
The Times of India · 2026-10-18
No headlines in this category right now — try “All”.